and mammalian target of rapamycin-dependent mechanism. J Biol Chem 2008; 283: 2203–2210

51. Lam QL, Liu S, Cao X et al. Involvement of leptin signaling in the survival and maturation of bone marrow-derived dendritic cells. Eur J Immunol 2006; 36: 3118–3130

52. Cohen G, Raupachova J, Wimmer T et al. The uraemic retention solute para-hydroxy-hippuric acid attenuates apoptosis of polymorpho-

© The Author 2010. Published by Oxford University Press on behalf of the ERA-EDTA. All rights reserved. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

The use of SDS–PAGE scanning of spent dialysate to assess uraemic toxin removal by dialysis

Alain Ficheux1, Nathalie Gayrard1, Ilan Szwarc2, Daniel Andress3, Stéphan Soullier1, Yohan Duny4, Gilles Goubert7, Marie Thomas2, Johanna Bismuth-Mondolfo2, Jean-Pierre Daurès4, Philippe Brunet5, Marie-Françoise Servel2 and Angel Argilès1,2

1RD – Néphrologie and Groupe Rein et HTA, EA3127, Institut Universitaire de Recherche Clinique IURC-UM1, 104, rue de la Galéra, Ecole Nationale Supérieure de Chimie, 34090 Montpellier, France, 2Centre de dialyse de Sète, Néphrologie Dialyse St Guilmel, 34204 Sète, France, 3Unitobio Laboratoire Andress Orbolato, 26, Avenue F. Mistral, 34112 Frontignan, France, 4Epidemiology and Biostatistics Department, EA 2415, IURC – Montpellier University I, Montpellier, France and 5Service de Néphrologie, Hôpital de La Conception – Université Aix-Marseille, 13005 Marseille, France

Correspondence and offprint requests to: Àngel Argilès; E-mail: argiles@rd-n.org

Abstract
Background. Uraemic toxins in the 8 to 60 kDa molecular weight range have been attracting increasing attention in dialysis therapy. However, there are no available standardized methods to evaluate their removal. Using new filtering membranes, we evaluated SDS–PAGE of spent dialysate to assess cut-off ranges and removal capacities into dialysate, while also measuring classical markers of dialyser function.

Methods. Eighteen dialysis patients were washed out for 2 weeks with FX 100 (Helixone®), followed by randomization to Xevonta Hi 23 (Amembris®) or FX dialysers for 2 weeks, then crossed over for an additional 2 weeks, and finally placed on Xenium 210 (Purema®) for 2 weeks. SDS–PAGE scanning of the removed proteins contained in the spent dialysate was performed during all dialysis sessions. Total mass of urea, creatinine, total proteins, beta 2 microglobulin (β2m), retinol-binding protein (RBP) and albumin were measured. The reduction rates of serum urea, creatinine, β2m, leptin, RBP, alpha 1-antitrypsin, albumin and total proteins were also determined.

Results. SDS–PAGE scanning identified four major protein peaks (10–18, 20–22.5, 23–30 and 60–80 kDa molecular weight) and showed clear differences in the amounts of removed proteins between the dialysers, particularly in the 20–22.5, 23–30 and 60–80 kDa ranges. Total mass of removed β2m, RBP and albumin were in agreement with SDS–PAGE, while serum assays showed differing results.

Conclusions. SDS–PAGE scanning provided a good characterization of protein patterns in the spent dialysate; it extended and agreed with protein determinations and allowed a better assessment of dialyser performance in removing 10 to 80 kDa molecular weight substances. It also identified differences between the three mainly filtering polysulfone dialysers that were not detected with blood measurements.

Keywords: haemodialysis; middle molecules; protein removal into dialysate; SDS–PAGE; spent dialysate

Introduction

Urea levels have classically been used as a marker of dialysis adequacy [1]. However, there is an impressive list of solutes that potentially contribute to uraemic toxicity [2], and this list is still growing [3]. Evidence for participation of these newly identified culprits in the development of uraemic syndrome and their association with morbidity and mortality has directed attention to other markers in the 8 to
60 kDa molecular weight range that may help to assess dialysis adequacy [4].

Molecules that are difficult to remove by dialysis, such as these larger middle molecular weight compounds and protein-bound molecules, play a significant role in uraemic toxicity [5]. Dialysis manufacturers have developed new dialysers having improved geometry and new membranes that enhance removal of middle molecular weight molecules with the aim of improving clinical outcomes [6,7]. However, there are presently no accepted methods that allow easy and precise measurement of removal capacities of uraemic retention solutes in the 8 to 60 kDa molecular weight range by these new generation dialysers. To evaluate dialyser performance, most authors determined variations in blood levels of particular proteins [8]; however, the majority of manufacturers limit information about dialyser performance to variations in blood levels of beta 2 microglobulin (β2m) which represents quite a restraint amount of information [4].

SDS–PAGE, which was first proposed by Laemmli in 1970 [9], is a reliable method for protein characterization that is easy to use and has been rendered widely available in the clinical setting. The aim of the present study was to assess the usefulness of scanning SDS–PAGE profiles of proteins contained in spent dialysate to evaluate the removal capacities of the new generation high-flux polysulfone dialysers in vivo during routine clinical haemodialysis.

Materials and methods

Patients

Eighteen stable dialysis patients treated in the dialysis centre at Néphrologie Dialyse St Guilhem in Sète were included in the study. They were dialysed three times a week with fully equipped AK200S machines (Gambro, Lund, Sweden) using ultrapure double reverse osmosis water and a measured dialysate flow of 500 ± 10 mL/min. They had been on dialysis for more than 3 months and had no active disease at the time of testing. The study was explained to the patients and they gave informed consent to participate in the protocol. This study was approved by the Comité de Protection des Personnes of Nîmes (2009.01.07 bis) and was given a registration number at the French Agency AFSSAPS 2008-A01612-53.

Study design

A schematic of the study design is given in Figure 1. Three new generation polysulfone dialysers were assessed. The complete in vitro characteristics of these dialysers are given in Table 1. After 2 weeks of wash out with FX 100 (Helixone® membrane, Fresenius Medical Care AG, Bad Homburg, Germany), the patients were randomized to Xevonta (Xevonta Hi 23, Amembris® membrane, B. Braun Avitum, Melsungen, Germany) (n = 9) or FX dialysers (n = 9) for 2 weeks and then crossed over for an additional 2 weeks. The eighteen patients were then switched to Xenium.

Table 1. Dialyser characteristics provided by the manufacturers from in vitro data

| Dialyser          | FX class 100 | Xenium 210 | Xevonta Hi 23 |
|-------------------|--------------|------------|--------------|
| Membrane (synthetic) | Helixone®     | Purena®    | Amembris®    |
| Wall thickness/inner diameter (μm) | 35/185 | 30/200 | 35/195 |
| Surface (m²) | 2.2          | 2.1        | 2.3          |
| In vitro K_{UF} | 73           | 80         | 124          |
| In vitro clearances (Qb/Qd: 300/500 mL/min) | | | |
| Urea | 278          | 285        | 279          |
| Creatinine | 261          | 272        | 276          |
| Phosphate | 248          | 253        | 277          |
| Vitamin B12 (1.4 kDa) | 192          | 200        | 204          |
| Inulin(5 kDa) | 142          | NA         | 144          |
| Myoglobin (16.7 kDa) | NA          | 55         | NA           |
| Sieving coefficient | | | |
| Vitamin B12 (1.4 kDa) | NA          | 0.99       | NA           |
| Inulin (5 kDa) | 1           | 0.89       | 1.0          |
| β2 microglobulin (11.8 kDa) | 0.8          | NA         | >0.8         |
| Myoglobin (16.7 kDa) | NA          | 0.24       | NA           |
| Albumin (65 kDa) | 0.001        | <0.01      | <0.001       |

NA, not available.
dialysers (Xenium 210, Purema® membrane, Baxter Healthcare Corporation, McGaw Park, IL, USA) for a final 2 weeks. The patients received routine dialysis prescription criteria that remained constant throughout the study period.

**Adsorption studies**

Polysulfone membranes are classically considered as filtering membranes. In addition to filtering, we also examined the adsorptive capacities of the new generation polysulfone membranes used in this study. Helixone®, Purema® and Amembris® dialysers were assessed for adsorption using the technique by Mares et al. [10]. At the end of dialysis procedures, after returning the blood to the patients, the dialysers were further rinsed with 2 L of saline. After draining, the dialysers were refilled with 3 mM EDTA (EDTA/PBS, pH 7.4), and the solution (volume 144 ± 26 mL) was recirculated at 80 mL/min for 30 min at room temperature to detach and remove adhering leukocytes. The dialysers were then drained and refilled with 40% acetic acid (volume 195 ± 15 mL), which was recirculated at 80 mL/min for 30 min at room temperature. The eluate was centrifuged to remove cellular detritus and albumin. Then, β2m and total protein concentration were determined in the supernatant as described below.

Results of the protein analysis from the adsorption experiments are shown in Table 2. These data indicate that the amount of total proteins adsorbed was always <5% of the total amount of proteins that were removed into the dialysate, confirming the filtrating abilities of the new polysulfone dialysers.

**Dialysate studies**

**Dialysate samples and solute mass removal assessment.** In order to assess total balance of the different substances from serum, continuous sampling of spent dialysate (CSSD) was performed during each dialysis treatment as previously reported by our group [11]. Samples were stored at −80°C until analysis. Urea, creatinine, total protein, albumin (67 kDa), retinol-binding protein (RBP) (21.2 kDa) and β2m (11.8 kDa) were determined from the collected spent dialysate, and the total mass removed of a given substance was calculated by multiplying the measured concentration by the total volume of dialysate that passed through the dialysers.

The three proteins selected are representative of three of the four molecular weight ranges of interest (see the SDS–PAGE analyses of the Results section) and provided an internal control for quantification of protein content assessed by SDS–PAGE. Since some of the proteins had a concentration under the sensitivity threshold for their respective assays, the spent dialysate was precipitated with 10% trichloroacetic acid. RBP and leptin were determined by ELISA using specific antibodies (RD Systems, Lille, France). Albumin was determined by immunoturbidimetry. The sensitivity threshold and the linearity range of the measurements of the different substances are given in Table 3.

### Table 2. Adsorptive capacities of the three dialysers used in the study

| Dialyser          | Adsorbed proteins (% of dialysate protein mass) | Adsorbed albumin (% of dialysate albumin mass) | Adsorbed β2m (% of dialysate β2m mass) |
|-------------------|-------------------------------------------------|-----------------------------------------------|---------------------------------------|
| FX 100 (Helixone) | 1.9%                                            | 0.5%                                          | 1.0%                                  |
| FX 100 (Helixone) | 2.5%                                            | 0.3%                                          | 0.1%                                  |
| Xenium 210 (Purema)| 1.2%                                            | 0.1%                                          | 0.2%                                  |
| Xenium 210 (Purema)| 3.5%                                            | 2.2%                                          | 0.8%                                  |
| Xevonta Hi 23 (Amembris) | 0.8%                                  | 0.2%                                          |                                       |
| Xevonta Hi 23 (Amembris) | 1.4%                                  | 0.4%                                          | 1.0%                                  |
| Mean              | 1.9%                                            | 0.6%                                          | 0.7%                                  |
| SE                | 0.4%                                            | 0.3%                                          | 0.2%                                  |
| Max               | 3.5%                                            | 2.3%                                          | 1.4%                                  |
| Min               | 0.8%                                            | 0.1%                                          | 0.1%                                  |

### Table 3. Laboratory analysis methods and their sensitivity and linearity

| Substance          | Measurement method | Linearity | Sensitivity | Dialysate (mean ± SD) [min–max] | Blood (mean ± SD) [min–max] |
|--------------------|--------------------|-----------|-------------|---------------------------------|-----------------------------|
| Urea (mmol/L)      | UV kinetic         | 0.8–50    | 0.38        | 4.6 ± 1.4 [1.3–9.3]             | 12 ± 8 [1.6–31]             |
| Creatinine (μmol/L)| Compensated Jaffe  | 5–2000    | 2.4         | 85 ± 2 [23–173]                | 406 ± 230 [73–939]          |
| β2 microglobulin (mg/L) | Immunoturbidimetry | 0.5–16    | 0.06        | 6.5 ± 7.1 [0.06–37]            | 13.5 ± 5.6 [3.2–23]         |
| Total proteins (diacylate) (g/L) | Photometric colour | 0.01–2.00 | 0.007       | 0.10 ± 0.06 [0.01–0.44]        |                             |
| Total proteins (mg/L) | Bradford           | 0–300     | 0.002       | 98 ± 60 [0.062–272]            |                             |
| Total proteins (mg/L) | Total protein (g/L) | 30–120    | 0.77        |                                |                             |
| Albumin ‘micro’ assays (mg/L) | Immunoturbidimetry | 5–300     | 0.46        | 12 ± 14 [0.1–113]              |                             |
| α-antitrypsin (g/L) | Immunoturbidimetry | 0.3–5.0   | 0.01        | 1.5 ± 0.3 [0.84–2.44]          | 25 ± 47 [0.6–386]          |
| Leptin (μg/L)      | ELISA              | 0.015–1   | 0.0078      | 13 ± 7 [1.4–44]                | 178 ± 96 [55–667]          |
| RBP (mg/L)         | ELISA              | 1.56–100  | 0.224       |                                |                             |

*Leptin and RBP were diluted before measurement in order to be in the linearity range.
Dialysance was obtained from DiascanTM and was iteratively measured during dialysis. We used a Fisher test with a covariance matrix model and compound symmetry that takes into account the repetitive nature of the data. Post-dialysis values were corrected using the formula of Bergstrom and Wehle [13]. Clearances (K) were obtained from dialysate mass (M), mean serum concentration (Cm) and time (t).

\[ K = \frac{M}{\langle Cm^2 \rangle} \] \( Kt/V \) was calculated from serum urea level as follows:

\[ Kt/V = \ln(Cpree/Cpost) \] [14].

Dialysance was obtained from DiascanTM and was iteratively measured during dialysis.

Statistics
Statistical analyses were performed using SAS V9.01 package (SAS Corporation, Cary, USA). Differences in the continuous variables among the three different dialysers were assessed using a variance analysis that included as a random effect and the dialysers as a fixed effect. Bonferroni’s test was used to assess differences between two of the three groups. P-values <0.05 were considered significant. Values are expressed as means ± standard error of the mean.

Results
The dialysis characteristics and the ability of the three dialysers to remove small molecular weight substances

Table 4. Dialysis characteristics and removal of small molecular weight solutes

|                      | Amembris® | Helixone® | Purema® |
|----------------------|-----------|-----------|---------|
| **Patient characteristics** |           |           |         |
| Age (years)          | 79 ± 1.7  |           |         |
| BW (kg)              |           |           |         |
| Before               | 68.8 ± 2.5| 68.8 ± 2.5| 68.4 ± 2.4|
| After                | 66.3 ± 2.3| 66.2 ± 2.3| 65.8 ± 2.3|
| WL                   | 2.5 ± 0.3 | 2.6 ± 0.3 | 2.6 ± 0.2 |
| **Dialysis characteristics** |           |           |         |
| t (min)              | 222 ± 3   | 222 ± 3   | 223 ± 3 |
| Qb (mL/min)          | 317 ± 2   | 318 ± 2   | 319 ± 2 |
| Qd (mL/min)          | 500 ± 10  | 500 ± 10  | 500 ± 10|
| Urea                 |           |           |         |
| Blood before (mmol/L)| 19.6 ± 0.9| 18.4 ± 0.8| 18.0 ± 0.9|
| Blood after (mmol/L) | 4.9 ± 0.3 | 4.5 ± 0.2 | 4.7 ± 0.3 |
| Blood RR (%)         | 75.1 ± 0.8| 75.2 ± 0.8| 74.2 ± 0.6|
| \( Kt/V \)           | 1.41 ± 0.03| 1.41 ± 0.03| 1.37 ± 0.03|
| Total mass removed (mmol/session) | 528 ± 20 | 533 ± 18 | 480 ± 20 |
| K (mL/min)           | 217 ± 5   | 217 ± 4   | 207 ± 2  |
| D (mL/min)           | 219 ± 2   | 218 ± 2   | 213 ± 1  |
| Creatinine           |           |           |         |
| Blood before (μmol/L)| 603 ± 25  | 620 ± 24  | 600 ± 25 |
| Blood after (μmol/L) | 196 ± 10  | 199 ± 9   | 197 ± 9  |
| Blood RR (%)         | 67.6 ± 0.8| 68.3 ± 0.8| 67.1 ± 0.9|
| Total mass removed (μmol/session) | 9645 ± 319 | 9862 ± 326 | 9292 ± 346 |
| K (mL/min)           | 119 ± 3   | 115 ± 3   | 113 ± 2  |

\*P < 0.05.
BW, body weight; WL, weight loss during dialysis; Qb, blood flow; Qd, dialysate flow; RR, reduction ratio; K, clearance; D, ionic dialysance; t, time; V, urea distribution volume.

are presented in Table 4. They were globally equivalent in their removal capacities of small molecular weight substances.

SDS–PAGE of spent dialysate
Examples of SDS–PAGE of proteins obtained from the spent dialysate from the different dialysers are presented in Figure 2A. A plotting of the density readings, presented as means ± SEM from the 80 to 10 kDa molecular weight range, is shown in Figure 2B. There were four major peaks corresponding to the 10 to 18, 20 to 22.5, 23 to 30 and 60 to 80 kDa molecular weight ranges. The variability on the density readings from patient to patient was quite low as indicated by the narrow SEM range. The amount of Coomassie blue-stained protein contained in each of these peaks, determined by scanning, is represented in Figure 3. These data indicate that Amembris® removed significantly more protein and particularly those contained in the 20 to 22.5, 23 to 30 and 60 to 80 molecular weight ranges.

Discussion
In the present study, we assessed the performances of three new generation, mainly filtrating, high-flux dialysers, having large surface areas, high water permeability and equiva-
Fig. 2. (A) Examples of 12.5% SDS–PAGE of the proteins in the spent dialysate from the three dialysers tested in the study [1—Xevonta Hi 23 (Amembris®); 2—FX 100 (Helixone®); 3—Xenium 210 (Purema®)]. (B) Scanning profiles of the SDS–PAGE gels of the different dialysers. The thick line represents the mean value from 18 patients and the thin line is the ±SEM. Protein amount in milligram is represented vertically and molecular weight is represented horizontally. The units of the readings have been normalized and arbitrarily fixed from 0 to 500. The correspondence from the reading to molecular weight was not linear and is presented on top of the graph. Four different peaks were observed that were at the same molecular weight ranges (10–18, 20–22.5, 23–30 and 60–80 kDa) which had different heights for the different dialysers. Numbering of the panels corresponds as follows: 1—Xevonta Hi 23 (Amembris®); 2—FX 100 (Helixone®); 3—Xenium 210 (Purema®).
Our results show that these three dialysers had similar capacities for removal of small molecular weight solutes but differed in their abilities to remove middle molecules (molecular weight range 8 to 60 kDa) into the dialysate. SDS–PAGE scanning of the spent dialysate showed that Amembris® removed significantly more middle weight proteins during routine dialysis.

Although the results of single proteins found in spent dialysate generally agreed with those from SDS–PAGE scanning, there were differences between the two tests. For example, although Amembris® and Helixone® removed similar amounts of RBP (21 kDa molecular weight), area under the curve measurements from SDS–PAGE scanning in the 20 to 22.5 kDa range showed clear differences between the two dialysers. Since SDS–PAGE includes analysis of all the Coomassie blue-stained proteins contained in the sample, it is thought to provide a more complete assessment of protein content in the dialysate than single protein measurements.

For removal of proteins into the dialysate in the 20 to 80 kDa range, SDS–PAGE scanning again revealed differences between the three dialysers that the assessment of blood levels of single proteins did not. For instance, there were no differences in serum levels of albumin (67 kDa) between the dialysers, whereas significant differences were observed in albumin removal into the dialysate. These differences in sensitivity in measuring dialyser performance may be due to at least two factors: the different sample types (blood and spent dialysate) and the different measurements (single protein determination versus total amount of proteins included in a range of molecular weight). The analysis of the spent dialysate allowed mass estimation of removal into the dialysate, while blood analysis of selected proteins provided a concentration measurement which is affected by multiple factors (compartamental distribution of the given protein, shifts in volume distribution during dialysis and other factors). Furthermore, for some particular proteins, such as albumin, the amount removed by dialysis is so minor compared to the total pool that no visible variations in serum levels would be expected, even when clear differences in removal into the dialysate exist. It may be that the non-circulating pool and/or generation rate is such that removed protein is quickly replaced. Thus, assessment of protein removal, using blood measurements, is difficult to interpret because of the multiple factors that affect this measurement.

Alternatively, measuring the removal by determining what has left the plasma requires analyzing what is adsorbed in the dialysis membrane as well as what passes across it and is recovered in the spent dialysate. The relative participation of these two mechanisms in determining total removal may vary markedly according to membrane characteristics. PMMA is the classical example of an adsorptive membrane [15], while polysulfone is the classical example of a filtering membrane [16–18]. Chanard et al. [16] assessed decreases in plasma radioactivity after injection of radiolabelled 131I-β2m. They showed that polysulfone was more efficient than PMMA in removing
radiolabelled β2m and demonstrated clear differences in adsorption between the dialysers. The radioactivity recovered from the PMMA membrane was about 90% of that removed from the plasma, while the radioactivity recovered from the polysulfone membrane was only about 10% of that removed from the plasma, and ~90% had accumulated in the ultrafiltrate. These studies clearly confirm the filtrating ability of the polysulfone dialysers. Because we used three polysulfone membranes with known filtration characteristics, analysis of the spent dialysate was the best method to evaluate removal. The error induced by adsorption onto the membrane over the total mass of the proteins removed of a defined molecular weight range is minimized when using polysulfone [17,18]. In our hands, the amount of protein recovered from the dialyser membrane while assessing adsorption (see Materials and methods section and Table 2) was <5% of the total mass of proteins that crossed the membrane and that were obtained in the spent dialysate (1.9 ± 0.4%, 0.6 ± 0.3% and 0.7 ± 0.2% for total proteins, albumin and β2m, respectively).

Table 5. Middle molecular weight solute removal

| Dialyser       | Xevonta Hi 23 | FX 100 | Xenium 210 |
|----------------|---------------|--------|------------|
| β2m            |               |        |            |
| Blood before (mg/L) | 18.4 ± 0.4   | 19.3 ± 0.4 | 18.6 ± 0.4 |
| Corrected blood after (mg/L) | 6.6 ± 0.3  | 8.0 ± 0.3  | 7.5 ± 0.3<sup>a</sup> <sup>b</sup>
| Blood RR (%)   | 64.3 ± 0.9    | 58.9 ± 1.0 | 59.9 ± 1.1<sup>b</sup> |
| Dialysate concentration (mg/L) | 1.29 ± 0.05 | 1.14 ± 0.07 | 0.99 ± 0.05<sup>b</sup> |
| Total dialysate mass (mg) | 146 ± 6 | 130 ± 8 | 110 ± 7<sup>b</sup> |
| K (mL/min)     | 51 ± 3        | 54 ± 3    | 30 ± 2<sup>b</sup> |
| Leptin         |               |        |            |
| Blood before (µg/L) | 34.7 ± 12.3  | 43.0 ± 17.5 | 26.0 ± 6.5 |
| Corrected blood after (mg/L) | 15.4 ± 5.1 | 18.2 ± 7.0 | 13.4 ± 2.9 |
| Blood RR (%)   | 31.8 ± 4.7    | 27.7 ± 5.2 | 28.7 ± 4.4 |
| RBP            |               |        |            |
| Blood before (mg/L) | 195.5 ± 26.6 | 160.4 ± 15.0 | 206.9 ± 20.5 |
| Corrected blood after (mg/L) | 142.2 ± 18.2 | 126.0 ± 13.6 | 163.9 ± 14.7 |
| Blood RR (%)   | 22.4 ± 4.0    | 20.6 ± 4.1 | 18.2 ± 2.5 |
| Dialysate concentration (mg/L) | 1.58 ± 0.20 | 1.19 ± 0.14 | 0.90 ± 0.07<sup>b</sup> |
| Total dialysate mass (mg) | 179.4 ± 23.4 | 136.5 ± 16.3 | 104.4 ± 8.7<sup>b</sup> |
| K (mL/min)     | 7.0 ± 1.2     | 4.8 ± 0.6   | 3.2 ± 0.4<sup>a</sup> |
| α1-Antitrypsin |               |        |            |
| Blood before (g/L) | 1.53 ± 0.05  | 1.50 ± 0.05 | 1.42 ± 0.04 |
| Corrected blood after (mg/L) | 1.38 ± 0.04 | 1.36 ± 0.04 | 1.29 ± 0.04 |
| Blood RR (%)   | 9.4 ± 0.9     | 8.9 ± 1.0   | 8.7 ± 0.9   |
| Albumin        |               |        |            |
| Blood before (g/L) | 36.9 ± 0.5   | 36.5 ± 0.5 | 36.7 ± 0.4 |
| Corrected blood after (g/L) | 33.6 ± 0.6 | 33.0 ± 0.5 | 33.5 ± 0.5 |
| Blood RR (%)   | 9.0 ± 0.9     | 9.2 ± 0.9   | 8.7 ± 0.8   |
| Dialysate concentration (mg/L) | 1.19 ± 0.14 | 0.80 ± 0.09 | 0.66 ± 0.04<sup>b</sup> |
| Total dialysate mass (mg) | 133.1 ± 15.7 | 89.4 ± 9.3 | 71.4 ± 5.4<sup>b</sup> |
| K (mL/min)     | 0.017 ± 0.003 | 0.017 ± 0.003 | 0.008 ± 0.001<sup>b</sup> |
| Total proteins |               |        |            |
| Blood before (g/L) | 64.6 ± 0.8   | 61.4 ± 0.8 | 64.1 ± 0.7<sup>c</sup> |
| Corrected blood after (g/L) | 58.7 ± 0.9 | 55.8 ± 0.7 | 58.5 ± 0.7<sup>c</sup> |
| Blood RR (%)   | 9.0 ± 0.8     | 8.8 ± 1.0   | 8.6 ± 0.9   |
| Dialysate concentration (mg/L) | 10.7 ± 0.7 | 7.1 ± 0.5  | 7.6 ± 0.4<sup>b</sup> |
| Total dialysate mass (mg) | 1209 ± 74 | 810 ± 55 | 809 ± 52<sup>b</sup> |
| K (mL/min)     | 0.09 ± 0.01   | 0.08 ± 0.01 | 0.05 ± 0.01<sup>b</sup> |

<sup>a</sup>P < 0.05 Xevonta vs FX.
<sup>b</sup>P < 0.05 Xevonta vs Xenium.
<sup>c</sup>P < 0.05 FX vs Xenium.

Blood measurements: reduction rate of the different serum proteins. The reduction rate for the measured proteins decreased from about 60% to <10% as molecular weight increased from 12 to 67 kDa. β2m reduction was significantly higher with Amembris® than with the other dialysers; serum levels of the other proteins showed a similar decrease in the three dialysers.

Fig. 5. Blood measurements: reduction rate of the different serum proteins. The reduction rate for the measured proteins decreased from about 60% to <10% as molecular weight increased from 12 to 67 kDa. β2m reduction was significantly higher with Amembris® than with the other dialysers; serum levels of the other proteins showed a similar decrease in the three dialysers.
Proteomics have previously been proposed as a promising analytical tool for recognizing specific peptide profiles in different pathological situations [19,20], to assess uraemic toxin removal and to identify new molecules with putative influences on uraemic toxicity [21]. Weissinger et al. [21] identified 1046 and 1394 polypeptides using low- and high-flux membranes, respectively, in the ultrafiltrate of one dialysed patient. However, this technique, perfectly adapted to identifying new markers of disease, is still reserved to a few specialized laboratories and it is not, at the present time, envisaged as a toll of wide use to quantify dialysis in a repetitive way in routine clinical practice.

Although SDS–PAGE technique provides semiquantitative data, it has previously been used to test protein permeability of different dialysers at various times during dialysis sessions using silver staining and laser densitometry [22]. For example, Mann and colleagues [22] used it to identify significant differences in permeability during individual dialysis sessions. In our study, we attempted to adapt SDS–PAGE into a reliable and easy-to-use method that can be performed in any dialysis unit to assess total amounts of middle weight molecules removed during a complete dialysis session.

To make this method easier, we adopted Coomassie blue staining of the gels. Although this technique is less sensitive than silver staining, it is not influenced by as many factors, it is technically simpler, and is not as expensive. To render it more reliable, we assessed the spent dialysate obtained by the CSSD, which we have previously shown to perfectly reflect the total spent dialysate [11]. Therefore, our current results did not show the intra-dialysis variations that had previously been observed [22], allowing us to accurately evaluate dialysis performance during a complete dialysis session, regardless of intra-session variability. The sensitivity provided by our method, using a standardized optical analysis over a molecular weight scale, proved to be satisfactory since it allowed identification of clear differences between the dialysers that could not be observed using other approaches (single protein determinations and blood measurements). Finally, the reliability of the method was supported by the small range of SEM observed in our analyses.

**Conclusion**

In summary, the present study showed that scanning the SDS–PAGE profile of middle weight molecules contained in the spent dialysate obtained by CSSD is a reliable and easy-to-use method that allowed identification of differences in behaviour of three new generation high permeability polysulfone dialysers. Using this method, we observed (i) very high efficacy and no difference in ability to remove small molecular weight compounds; (ii) that Amembris® removed significantly more proteins at all weight ranges than Purema®, but only at higher molecular weights than Helixone®; (iii) that Amembris® and Helixone® removed significantly more β2m than Purema®, which agrees with the SDS–PAGE scanning results, and that Amembris® removed more total proteins than the other two dialysers; (iv) that β2m reduction differed among the three dialysers only when measuring serum levels of the representative proteins, indicating that serum levels may be influenced by many factors other than removal into dialysate; therefore, (v) measurement of serum levels of single proteins is not the best approach to assess uraemic toxin removal capacities by new dialysers, particularly for the middle weight molecules. Since adsorption contributes to <5% of total protein removal and was equivalent in the three dialysers, the differences in dialyser performance were due to differences in removal into the dialysate.

Many different substances are removed from the plasma; some of these are uraemic retention solutes, some may be considered toxins [2] and some may even have beneficial properties. Therefore, to establish the benefits or drawbacks of substance removal, it will be necessary to better identify, probably using MS-based techniques, the complete array of substances removed. However, it may be easier to install and perform SDS–PAGE in a dialysis unit than other techniques that require more complex technologies. The use of SDS–PAGE scanning of spent dialysate in many dialysis units would enlarge our knowledge about how the different dialysis settings are able to remove uraemic toxins of greater importance (8–60 kDa molecular weight range).

**Acknowledgements.** The authors thank Priscilla Martinez and the staff of the NDSG dialysis centre for their participation and assistance during the trial. Dr Peter G Kerr’s help in reviewing the manuscript is deeply appreciated.

**Conflict of interest statement.** B. Braun Avitum participated in the fees generated to perform the study. The Centre de Néphrologie et de Transplantation of the Hospital ‘La Conception’ receives funding from Baxter, Fresenius, Méditor, Gambro and Hemotech for various clinical projects.

**References**

1. Lowrie EG, Laird NM, Parker TF et al. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. *N Engl J Med* 1981; 305: 1176–1181
2. Vanholder R, De Smet R, Glorieux G et al for the European Uremic Toxin Work Group (EUTox). Review on uraemic toxins: classification, concentration, and interindividual variability. *Kidney Int* 2003; 63: 1934–1943
3. European Uremic Toxins Work Group (EUTox). Uremic Solutes Database. http://www.nephro-leipzig.de/eutoxdb/index.php (17 November 2010, last accessed date)
4. Vanholder R, Eloot S, Van Biesen W. Do we need new indicators of dialysis adequacy based on middle-molecule removal? *Nat Clin Pract Nephrol* 2008; 4: 174–175
5. Vanholder R, Baumsteiner U, Brunet P et al for the European Uremic Toxin Work Group. A bench to bedside view of uraemic toxins. *J Am Soc Nephrol* 2008; 19: 863–870
6. Clark WR, Ronco C. Determinants of haemodialysis performance and the potential effect on clinical outcome. *Nephrol Dial Transplant* 2001; 16: 56–60
7. Locatelli F, Martin-Malo A, Hannedouche T et al. Effect of membrane permeability on survival of hemodialysis patients. *J Am Soc Nephrol* 2009; 20: 645–654
8. Krieter DH, Lemke HD, Wanner C. A new synthetic dialyzer with advanced permeselectivity for enhanced low-molecular weight protein removal. *Artif Organs* 2008; 32: 547–554
Sleep-disordered breathing predicts cardiovascular events and mortality in hemodialysis patients

Takahiro Masuda1,2, Mitsunobu Murata3, Sumiko Honma1, Yoshitaka Iwazu1,2, Nobuhiro Sasaki1,2, Manabu Ogura2, Akira Onishi2, Yasuhiro Ando2, Shigeaki Muto3, Kazuyuki Shimada4, Kazuomi Kario3, Eiji Kusano5 and Yasushi Asano4

1Department of Nephrology, Japanese Red Cross Koga Hospital, Koga, Ibaraki, Japan, 2Division of Nephrology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan and 3Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan

Correspondence and offprint requests to: Mitsunobu Murata; E-mail: mmurata@jichi.ac.jp

Abstract

Background. Sleep-disordered breathing (SDB), characterized by repetitive apnea and hypopnea during sleep, is a risk factor for cardiovascular disease. However, the links between SDB and cardiovascular events in hemodialysis (HD) patients have not been clearly evaluated.

Methods. We followed the clinical outcome of 94 HD patients, who underwent overnight pulse oximetry on dialysis day. The SDB group was defined as 3% oxygen desaturation index (ODI) over five events per hour, and the others were the normal group. The primary outcome was cardiovascular events and death. We used Kaplan–Meier curve and Cox proportional hazard model for survival analyses.

Results. Forty-four patients (46.8%) were classified into the SDB group. Body mass index, diabetes mellitus, 3% ODI and Epworth sleepiness scale were significantly higher, and duration of dialysis, Kt/V, normalized protein catabolism rate and hemoglobin were lower in the SDB group than in the normal group. During a median 55 months of follow-up, Kaplan–Meier analysis revealed that the SDB group had a significantly higher rate of cardiovascular events and all-cause mortality than the normal group. Age, cardiothoracic ratio, serum albumin and 3% ODI were predictors of cardiovascular events and all-cause mortality at univariate Cox regression analysis. In the adjusted analysis, SDB is an independent predictor of increased cardiovascular events (hazard ratio 3.10; 95% confidence interval (CI), 1.35–7.12; P = 0.008) and all-cause mortality (hazard ratio 2.81; 95% CI, 1.07–7.41; P = 0.037).

Conclusions. SDB is an independent risk factor for cardiovascular events and mortality in HD patients. Effective and